Filip Dubovsky

7.0k total citations · 1 hit paper
53 papers, 2.6k citations indexed

About

Filip Dubovsky is a scholar working on Epidemiology, Infectious Diseases and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Filip Dubovsky has authored 53 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Epidemiology, 13 papers in Infectious Diseases and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Filip Dubovsky's work include Respiratory viral infections research (28 papers), Influenza Virus Research Studies (15 papers) and Pneumonia and Respiratory Infections (15 papers). Filip Dubovsky is often cited by papers focused on Respiratory viral infections research (28 papers), Influenza Virus Research Studies (15 papers) and Pneumonia and Respiratory Infections (15 papers). Filip Dubovsky collaborates with scholars based in United States, United Kingdom and Spain. Filip Dubovsky's co-authors include Therese Takas, Mark T. Esser, Tonya Villafana, M. Pamela Griffin, Anis A. Khan, Joseph B. Domachowske, Judith Falloon, Elissa Malkin, Tingting Yi and Yuan Yuan and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and PLoS ONE.

In The Last Decade

Filip Dubovsky

51 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

2020 456 citations M. Pamela Griffin, Yuan Yuan et al. profile →

Peers

Countries citing papers authored by Filip Dubovsky

Since Specialization

Citations

This map shows the geographic impact of Filip Dubovsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Filip Dubovsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Filip Dubovsky more than expected).

Fields of papers citing papers by Filip Dubovsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Filip Dubovsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Filip Dubovsky. The network helps show where Filip Dubovsky may publish in the future.

Co-authorship network of co-authors of Filip Dubovsky

This figure shows the co-authorship network connecting the top 25 collaborators of Filip Dubovsky. A scholar is included among the top collaborators of Filip Dubovsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Filip Dubovsky. Filip Dubovsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin–Matrix-M® nanoparticle vaccine induces neutralizing responses in nonhuman primates 2025 ·Nature Communications ·Nita Patel, (unknown), (unknown), Rhonda Flores, (unknown), Mimi Guebre‐Xabier, Haixia Zhou, Bin Zhou, Kelsey Jacobson, Desheng Jiang, Xiaoyun Bai, Rafia Khatoon, (unknown), James A. Norton, (unknown), (unknown), (unknown), Filip Dubovsky, Gale Smith	0
2	Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial 2021 ·PLoS Medicine ·Neil Formica, Raburn M. Mallory, Gary Albert, (unknown), Joyce S. Plested, Iksung Cho, Andreana Robertson, Filip Dubovsky, Gregory M. Glenn, (unknown)	64
3	A study to evaluate the immunogenicity and shedding of live attenuated influenza vaccine strains in children 24–<48 months of age 2019 ·Vaccine ·Raburn M. Mallory, Andrew C. Nyborg, Rubana N. Kalyani, Yuan Yuan, Stan L. Block, Filip Dubovsky	9
4	Phase 1 study of MEDI3902, an investigational anti–Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults 2018 ·Clinical Microbiology and Infection ·Omar Ali, Xiang‐Qing Yu, Gabriel J. Robbie, Yuling Wu, Kathryn Shoemaker, Li Yu, Antonio DiGiandomenico, Ashley Keller, Chuka Anude, Martha Hernandez‐Illas, Terramika Bellamy, Judith Falloon, Filip Dubovsky, Hasan S. Jafri	92
5	Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults 2016 ·Antimicrobial Agents and Chemotherapy ·M. Pamela Griffin, Anis A. Khan, Mark T. Esser, Kathryn Jensen, Therese Takas, Martin Kankam, Tonya Villafana, Filip Dubovsky	113
6	Safety and immunogenicity of a live attenuated intranasal vaccine against respiratory syncytial virus in healthy RSV seronegative children 5 to 24 months of age. 2013 ·PLoS ONE ·Elissa Malkin, Ram Yogev, Nazha Abughali, Joseph Sliman, (unknown), (unknown), C. Yang, (unknown), Mark T. Esser, Roderick S. Tang, Filip Dubovsky	6
7	Safety and Immunogenicity of a Live Attenuated RSV Vaccine in Healthy RSV-Seronegative Children 5 to 24 Months of Age 2013 ·PLoS ONE ·Elissa Malkin, Ram Yogev, Nazha Abughali, Joseph Sliman, (unknown), (unknown), (unknown), Mark Eickhoff, Mark T. Esser, Roderick S. Tang, Filip Dubovsky	58
8	The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing 2012 ·European Journal of Clinical Microbiology & Infectious Diseases ·Christopher S. Ambrose, Filip Dubovsky, Tingting Yi, Robert B. Belshe, Shai Ashkenazi	28
9	Immunogenicity and Safety of a Quadrivalent Live Attenuated Influenza Vaccine in Children 2012 ·The Pediatric Infectious Disease Journal ·Stan L. Block, Judith Falloon, (unknown), Leonard R. Krilov, Filip Dubovsky, Tingting Yi, Robert B. Belshe	58
10	A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults 2011 ·Vaccine ·Stan L. Block, Tingting Yi, Eric Sheldon, Filip Dubovsky, Judith Falloon	50
11	PHASE-I STUDY MEDI-534, OF A LIVE, ATTENUATED INTRANASAL VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS AND PARAINFLUENZA-3 VIRUS IN SEROPOSITIVE CHILDREN 2009 ·The Pediatric Infectious Disease Journal ·Margarita Gomez, Maurice A. Mufson, Filip Dubovsky, (unknown), Wen Zeng, Genevieve A. Losonsky	56
12	Quantitative Detection of Plasmodium falciparum DNA in Saliva, Blood, and Urine 2009 ·The Journal of Infectious Diseases ·Davis Nwakanma, Natalia Gomez‐Escobar, Michael Walther, Sarah Crozier, Filip Dubovsky, Elissa Malkin, Emily Locke, David J. Conway	75
13	Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720 2007 ·Parasite Immunology ·Allan Saul, Meike Hensmann, Jetsumon Sattabongkot, William E. Collins, John W. Barnwell, Jan A. M. Langermans, Yimin Wu, Carole A. Long, Filip Dubovsky, A. W. Thomas	23
14	Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial 2007 ·Trials ·Eusébio Macete, Jahit Sacarlal, John J. Aponte, Amanda Leach, Margarita M. Navia, Jessica Milman, Caterina Guinovart, Inácio Mandomando, (unknown), Marc Lievens, Alex Owusu‐Ofori, Marie‐Claude Dubois, (unknown), Marguerite Koutsoukos, (unknown), Ricardo Thompson, Filip Dubovsky, W. Ripley Ballou, Joe Cohen, Pedro L. Alonso	25
15	Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1–4 in Mozambique 2006 ·Tropical Medicine & International Health ·Eusébio Macete, John J. Aponte, Caterina Guinovart, Jahit Sacarlal, Opokua Ofori‐Anyinam, Inácio Mandomando, Mateu Espasa, (unknown), Amanda Leach, Marie‐Claude Dubois, D. Gray Heppner, (unknown), Jessica Milman, Joe Cohen, Filip Dubovsky, Nadia Tornieporth, R. Thompson, Pedro L. Alonso	30
16	RTS,S/AS02A Malaria Vaccine Does Not Induce Parasite CSP T Cell Epitope Selection and Reduces Multiplicity of Infection 2006 ·PubMed ·Sónia Enosse, Carlota Dobaño, (unknown), John J. Aponte, Marc Lievens, Amanda Leach, Jahit Sacarlal, Brian Greenwood, Jessica Milman, Filip Dubovsky, Joe Cohen, Ricardo Thompson, W. Ripley Ballou, Pedro L. Alonso, David J. Conway, Colin J. Sutherland	53
17	Progress towards the development of malaria vaccines 2006 ·Trends in Parasitology ·Elissa Malkin, Filip Dubovsky, (unknown)	35
18	Potency assay design for adjuvanted recombinant proteins as malaria vaccines 2006 ·Vaccine ·Birgitte Giersing, Filip Dubovsky, Allan Saul, (unknown), Philip D. Minor, Bruce D. Meade	20
19	Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques 2005 ·Vaccine ·Jan A. M. Langermans, Annette M. Schmidt, Richard A. W. Vervenne, Ashley J. Birkett, J. Mauricio Calvo‐Calle, Meike Hensmann, George B. Thornton, Filip Dubovsky, H. Weiler, Elizabeth Nardin, Alan W. Thomas	22
20	Heterogeneous Virulence of EnteroaggregativeEscherichia coliStrains Isolated from Children in Southwest Nigeria 2000 ·The Journal of Infectious Diseases ·Iruka N. Okeke, Adebayo Lamikanra, John R. Czeczulin, Filip Dubovsky, James B. Kaper, James P. Nataro	150

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact